Lexicon adds type 1 diabetes data to boost its dual SGLT1/2 inhibitor
This article was originally published in Scrip
Lexicon Pharmaceuticals has announced positive top-line data for its dual SGLT1/2 inhibitor LX4211 in type 1 diabetes patients to add to the promising results seen in type 2 diabetes reported last October (scripintelligence.com, 2 October 2013).
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.